PD-L1 / TCR Activator - CHO Recombinant Cell Line

Catalog #

60536

$11,375 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

PD-L1/TCR Activator-CHO Recombinant Cell Line is a CHO-K1 cell line constitutively expressing human PD-L1 (Programmed Cell Death 1 Ligand 1, CD274 or B7 homolog 1 (B7-H1), GenBank accession #NM_014143) and an engineered TCR (T cell receptor) activator.

This cell line was functionally validated with Anti-PD-1 and Anti-PD-L1 neutralizing antibodies in co-culture assays.

PD-L1 CHO Cell Line TCR Activator BPS Bioscience

Figure 1: Mechanism of action of PD-L1/TCR Activator CHO Recombinant Cell Line in a co-culture assay.
The TCR activator present at the surface of PD-L1/TCR Activator CHO cells stimulate TCR in Jurkat T cells, whereas overexpression of PD-L1 on the CHO cell line engages Jurkat PD-1, blocking TCR activation signaling and preventing activation of NFAT. Addition of a neutralizing anti-PD-1 or anti-PD-L1 antibody to the co-culture releases the PD-L1/PD-1 complex and results in TCR activation and increased NFAT activity, which translates into increased luciferase reporter signal.

This product has been cited 17 times.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Synonyms

Programmed Cell Death 1 Ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, CD274, PDCD1L1

●

Product Data Gallery

Effect of Anti-PD-1 Neutralizing Antibody on NFAT activation in the PD-1/NFAT Reporter Jurkat Recombinant Cell Line in co-culture with PD-L1/ TCR Activator – CHO Recombinant Cell Line.

Dose-response curve of PD-1/NFAT Reporter Jurkat Recombinant Cell Line to Anti-PD-1 Neutralizing Antibody in co-culture with PD-L1/ TCR Activator – CHO Recombinant Cell Line.

Dose-response curve of PD-1/NFAT Reporter Jurkat Recombinant Cell Line co-cultured with PD-L1/TCR Activator-CHO Recombinant Cell Line to Nivolumab (anti-PD-1).

Effect of Anti-PD-L1 Neutralizing Antibody on NFAT activation in the PD-1/NFAT Reporter Jurkat Recombinant Cell Line co-cultured with PD-L1/ TCR Activator – CHO Recombinant Cell Line.

Dose response curve of PD-1/NFAT Reporter Jurkat Recombinant Cell Line to PD-L1 Neutralizing Antibody co-cultured with PD-L1/ TCR Activator – CHO Recombinant Cell Line.

Product Info

Storage and Usage

Citations17

Host Cell Line

CHO-K1 cells, Chinese Hamster Ovary, epithelial-like cells, adherent

Supplied As

Each vial contains >1 x 10⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience, #79796)

Materials Required But Not Supplied

Media Required for Cell Culture

Name	Ordering Information
Thaw Medium 3	BPS Bioscience #60186
Growth Medium 3A	BPS Bioscience #60188

Materials Required for Cellular Assay

Name	Ordering Information
Thaw Medium 2	BPS Bioscience #60184
PD-1/NFAT Reporter -Jurkat Recombinant Cell Line	BPS Bioscience #60535
NFAT Reporter (Luc) -Jurkat Recombinant Cell Line	BPS Bioscience #60621
Anti-PD-1 Neutralizing Antibody	BPS Bioscience #71120
Nivolumab (anti-PD-1)	SelleckChem #A2002
Anti-PD-L1 (CD274) Neutralizing Antibody	BPS Bioscience #71213
96-well tissue culture-treated white clear-bottom assay plate
ONE-Step™ Luciferase Assay System	BPS Bioscience #60690
Luminometer

UniProt #

Q9NZQ7

Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

PD-L1 and PD-L2 binding to PD-1, a receptor expressed on T-cells, negatively regulates immune responses. The PD-1 ligands PD-L1 and PD-L2 are found on the surface of most cancer cells, and their interaction with the receptor PD-1 inhibits T cell activity and allows cancer cells to escape immune surveillance. This pathway is also involved in regulating autoimmune responses. Therefore, these proteins (termed immune checkpoints) are promising therapeutic targets for many types of cancer as well as multiple sclerosis, arthritis, lupus, and type I diabetes. Checkpoint inhibitors have remarkable efficacy in a wide range of cancer types and have revolutionized cancer treatment. The PD-1 inhibitors nivolumab, pembrolizumab, cemiplimab and PD-L1 inhibitors atezolizumab, avelumab, and durvalumab are all FDA-approved drugs for immuno-therapy.

References

Sasca D., et al. 2019 Blood 133: 2305-2319

Storage/Stability

Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at [email protected] if the cells are not frozen in dry ice upon arrival.

Growth Media

For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.

Media Required for Cell Culture

Thaw Medium 3 (BPS Bioscience #60186): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin

Growth Medium 3A (BPS Bioscience #60188): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 1 mg/ml of Geneticin and 500 μg/ml of Hygromycin B to ensure recombinant expression.

Media Required for Functional Cellular Assay

Thaw Medium 2 (BPS Bioscience #60535): RPMI 1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin.

Applications

Screen for activators or inhibitors of PD-1 signaling in a cellular model.
Characterize the biological activity of PD-1 and interaction with its ligands.

Shipping Temperature

-80°C

Notes

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles

Scientific Category

Immunotherapy

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

PD-L1 / TCR Activator - CHO Recombinant Cell Line

PRODUCTS

SERVICES

RESOURCES

COMPANY